E25.0

Congenital adrenogenital disorders associated with enzyme deficiency

Billable FY2026 2025-10-01 → 2026-09-30

Exclusions 5 never code together

E25code

Excludes1

indeterminate sex and pseudohermaphroditism (Q56)Q56
chromosomal abnormalities (Q90-Q99)Q90-Q99

E20-E35block

Excludes1

galactorrhea (N64.3)N64.3
gynecomastia (N62)N62

E00-E89chapter

Excludes1

transitory endocrine and metabolic disorders specific to newborn (P70-P74)P70-P74

Excludes1 — never code together. The excluded condition and this one are mutually exclusive.

Instructional notes 11

E25.0code

Inclusion terms

Congenital adrenal hyperplasia
21-Hydroxylase deficiency
Salt-losing congenital adrenal hyperplasia

E25code

Includes

adrenogenital syndromes, virilizing or feminizing, whether acquired or due to adrenal hyperplasia consequent on inborn enzyme defects in hormone synthesis
Female adrenal pseudohermaphroditism
Female heterosexual precocious pseudopuberty
Male isosexual precocious pseudopuberty
Male macrogenitosomia praecox
Male sexual precocity with adrenal hyperplasia
Male virilization (female)

E00-E89chapter

Notes

All neoplasms, whether functionally active or not, are classified in Chapter 2. Appropriate codes in this chapter (i.e. E05.8, E07.0, E16-E31, E34.-) may be used as additional codes to indicate either functional activity by neoplasms and ectopic endocrine tissue or hyperfunction and hypofunction of endocrine glands associated with neoplasms and other conditions classified elsewhere.E05.8 E07.0 E16-E31 E34.-

Index entries leading here 14

Deficiency, deficient
- 11-hydroxylase E25.0
- 21-hydroxylase E25.0
- 3-beta hydroxysteroid dehydrogenase E25.0
Defect, defective Q89.9
- 11-hydroxylase E25.0
- 21-hydroxylase E25.0
- 3-beta-hydroxysteroid dehydrogenase E25.0
Hyperplasia, hyperplastic
- adrenal (capsule) (cortex) (gland) E27.8
  - congenital E25.0
    - salt-losing E25.0
  - with
    - sexual precocity (male) E25.9
      - congenital E25.0
    - virilism, adrenal E25.9
      - congenital E25.0
    - virilization (female) E25.9
      - congenital E25.0
Pseudohermaphroditism Q56.3
- female Q56.2
  - adrenal (congenital) E25.0
Hyperfunction
- adrenal cortex, not associated with Cushing's syndrome E27.0
  - virilism E25.9
    - congenital E25.0
Syndrome — see also Disease
- adrenogenital E25.9
  - congenital, associated with enzyme deficiency E25.0
Adrenogenitalism, congenital E25.0
Adrenogenital syndrome E25.9
- congenital E25.0
- salt loss E25.0
Masculinization (female) with adrenal hyperplasia E25.9
- congenital E25.0
Precocity, sexual (constitutional) (cryptogenic) (female) (idiopathic) (male) E30.1
- with adrenal hyperplasia E25.9
  - congenital E25.0
Macrogenitosomia (adrenal) (male) (praecox) E25.9
- congenital E25.0
Hyperadrenocorticism E24.9
- congenital E25.0
Virilism (adrenal) E25.9
- congenital E25.0
Virilization (female) (suprarenal) E25.9
- congenital E25.0

Alongside this code 2 same parent — E25

E25.8 Other adrenogenital disorders E25.9 Adrenogenital disorder, unspecified

Medications 1

2 Congenital Cranial Dysinnervation Disorders drugs

MED-RT files conditions by MeSH, which carves the world differently from ICD-10. These are name matches on this code's description, offered as candidates — not as an assertion that they are this code.

Additional references

AHA Coding Clinic® Licence required

Official coding advice for this code. Published by the American Hospital Association. Not included in this installation.

Risk adjustment

CMS22HCC23 ESRD21HCC23 ESRD24HCC23 RX08HCC43

Presence is a property of the code. Untick a model to hide it everywhere.

This code

Billable: yes
Code set: FY2026
Parent: E25
Block: E20-E35
Siblings: 2

Present FY2024–FY2027.